Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

We recently compiled a list of the 7 Blue Chip Stocks with Low PE Ratios. In this article, we are going to take a look at ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Keytruda succeeds n a Phase 3 trial for head and neck cancer, showing promising results for event-free survival, the study's ...